The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball, Susan; Vickery, J; Hobart, J; et al.Wright, D; Green, C; Shearer, J; Nunn, A; Gomez Cano, M; MacManus, D; Miller, D; Mallik, S; Zajicek, J
Date: 1 February 2015
Health Technology Assessment
NIHR Health Technology Assessment Programme
The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial aimed to determine whether or not oral Δ(9)-tetrahydrocannabinol (Δ(9)-THC) slowed the course of progressive multiple sclerosis (MS); evaluate safety of cannabinoid administration; and, improve methods for testing treatments in progressive MS.
Institute of Health Research
Collections of Former Colleges
Item views 0
Full item downloads 0